find a clinical trial
If you have any questions or are interested in participating in one of our Clinical Trials, please take note of the associated protocol number and contact our team at 201-518-3587, or email us.
34
Clinical Trials
Leukemia
Phase II
Active
nct/study# NA / ASTX727-07
This Is A Single-Arm, Open-Label, Multicenter, Non- Randomized Interventional Study To Evaluate The Pharmacokinetic (PK) Interaction, Safety, And Preliminary Efficacy Of ASTX727 When Given In Combination With Venetoclax For The Treatment Of Actively Diagnosed Acute Myeloid Leukemia (AML) In Adults Who Are Age 75 Years Or Older, Or Who Have Comorbidities That Preclude Use Of Intensive Induction Chemotherapy.
Learn More
Leukemia
Phase III
Accepting Patients
nct/study# NCT04472598 / M16-191
Abbvie, Protocol: M16-191, PI: Dr. Mccloskey, Title A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Of Navitoclax In Combination With Ruxolitinib Versus Ruxolitinib In Subjects With Myelofibrosis (TRANSFORM-1)
Learn More
Leukemia
Phase III
Accepting Patients
nct/study# NCT04468984 / M20-178
Abbvie, Protocol: M20-178, PI: Dr. Mccloskey, A Randomized, Open-Label, Phase 3 Study Evaluating Efficacy And Safety Of Navitoclax In Combination With Ruxolitinib Versus Best Available Therapy In Subjects With Relapsed/Refractory Myelofibrosis (TRANSFORM-2)
Learn More
Leukemia
NA
Accepting Patients
nct/study# NCT04256317 / ASTX030-01
A Multi-Phase, Dose-Escalation Followed By An Open-Label, Randomized, Crossover Study Of Oral ASTX030 (Cedazuridine And Azacitidine Given In Combination) Versus Subcutaneous Azacitidine In Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), Or Acute Myeloid Leukemia (AML)
Learn More
Leukemia
Phase II
Accepting Patients
nct/study# NCT04093570 / ASTX727-06
An Open-Label, Multicenter, Extension Study For Subjects Who Participated In Prior Clinical Studies Of ASTX727 (Standard Dose)
Learn More
Leukemia
Phase I
Accepting Patients
nct/study# NCT04310592 / CYNK-001-AML-001
A Phase I Multi-Dose Study Of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK-001) In Adults With Actively Diagnosed Primary Or Secondary Acute Myeloid Leukemia (AML) In Morphologic Complete Remission With Minimal Residual Disease (MRD)
Learn Morewe are here for you
For more information or to schedule an appointment,
call 844-346-7222. You can also schedule an appointment by calling the RCCA location nearest you.
Regional Cancer Care Associates is one of fewer than 200 medical practices in the country selected to participate in the Oncology Care Model (OCM); a recent Medicare initiative aimed at improving care coordination and access to and quality of care for Medicare beneficiaries undergoing chemotherapy treatment.